Caprock Group LLC Purchases Shares of 755 argenex SE $ARGX

Caprock Group LLC acquired a new position in argenex SE (NASDAQ:ARGX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 755 shares of the company’s stock, valued at approximately $538,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its holdings in shares of argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after buying an additional 47 shares during the last quarter. MAI Capital Management increased its position in argenex by 866.7% during the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after acquiring an additional 78 shares during the period. Mather Group LLC. acquired a new position in argenex during the 3rd quarter valued at $50,000. TD Private Client Wealth LLC boosted its holdings in argenex by 750.0% in the 3rd quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after purchasing an additional 75 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the period. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ARGX shares. TD Cowen boosted their price objective on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. DZ Bank upgraded argenex to a “strong-buy” rating in a research note on Friday, December 19th. Robert W. Baird downgraded argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Finally, Evercore upped their target price on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $986.78.

argenex Stock Performance

Shares of ARGX opened at $843.55 on Wednesday. The company has a market cap of $52.20 billion, a price-to-earnings ratio of 36.22, a PEG ratio of 0.71 and a beta of 0.37. The stock has a fifty day moving average price of $833.64 and a two-hundred day moving average price of $804.22. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.